Small Pharma
Pipeline of novel patent-protected deuterium-enriched tryptamine compounds for psychedelic-assisted psychotherapy as a rapid onset, sustained treatment for mental health disorders.
Launch date
Employees
Market cap
$36.9m
Enterprise valuation
$28m (Public information from Oct 2023)
Share price
CAD0.15 DMT.V
Company register number 09420724
London England (HQ & founding location)
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Revenues | <1m | <1m | - | - |
% growth | - | 4 % | - | - |
EBITDA | (4.0m) | (3.7m) | (12.0m) | (16.4m) |
% EBITDA margin | (8000 %) | (7232 %) | - | - |
Profit | - | (4.7m) | (14.8m) | (15.2m) |
% profit margin | - | (9061 %) | - | - |
R&D budget | - | 1.3m | 3.2m | 7.6m |
R&D % of revenue | - | 2473 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
£830k | Seed | ||
* | N/A Valuation: CAD240m 3200.0x EV/LTM Revenues -40.0x EV/LTM EBITDA | IPO | |
* | N/A | Acquisition | |
Total Funding | $1.1m |
Recent News about Small Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.